Sugi Predict

Sugi Predict / Compounds / Prazepine

Prazepine

Prazepine

SCHEMBL2109939

CN(C)CCCN1Cc2ccccc2Cc2ccccc21

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 8/20 0.55
▸ HTR2A P28223 7/20 0.55
▸ SLC6A4 P31645 7/20 0.55
▸ LMNA P02545 5/20 0.55
▸ MAPT P10636 5/20 0.55
▸ HTR2C P28335 5/20 0.55
▸ CYP2D6 P10635 4/20 0.55
▸ DRD2 P14416 4/20 0.55
▸ ADRA1A P35348 4/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ SLC22A1 O15245 3/20 0.55
▸ CHRM2 P08172 3/20 0.55
▸ CHRM4 P08173 3/20 0.55
▸ HTR1A P08908 3/20 0.55
▸ CHRM5 P08912 3/20 0.55
▸ CHRM1 P11229 3/20 0.55
▸ ADRA2B P18089 3/20 0.55
▸ ADRA2C P18825 3/20 0.55
▸ CHRM3 P20309 3/20 0.55
▸ DRD1 P21728 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7843815 0.80 ALDH1A1 (0.41) HRH1HTR2ASLC6A4LMNAMAPT
Mezepine SCHEMBL38660320 0.79 SLC6A2 (0.55) HRH1HTR2ASLC6A4HTR2CCYP2D6
Mezepine SCHEMBL2110147 0.79 SLC6A2 (0.55) HRH1HTR2ASLC6A4HTR2CCYP2D6
Enprazepine SCHEMBL2110018 0.78 HRH1 (0.51) HRH1HTR2ASLC6A4LMNAMAPT
Enprazepine SCHEMBL31438605 0.78 HRH1 (0.51) HRH1HTR2ASLC6A4LMNAMAPT
SCHEMBL8951821 0.78 SLC6A4 (0.51) HRH1HTR2ASLC6A4LMNAMAPT
SCHEMBL28863147 0.78 MAPT (0.82) HRH1HTR2ASLC6A4LMNAMAPT
SCHEMBL11474941 0.74 SLC6A4 (0.50) HRH1HTR2ASLC6A4LMNAMAPT
SCHEMBL28284590 0.74 SLC6A4 (0.65) HRH1HTR2ASLC6A4LMNAMAPT
Hydrochloric Acid SCHEMBL11475198 0.73 LMNA (0.51) HRH1HTR2ASLC6A4LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112876487-B Conjugated pazemidine corrosion inhibitor and preparation method thereof 泰州先进化工有限公司 2022-02-15 — — CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
CN-120091810-A Methods and highly bioavailable permeable compounds for treating viral diseases 基里尔·迪丹克 2025-06-03 — — CN disclosed
CN-119894533-A Methods and compositions for activating, modulating and regulating weight loss and therapeutic uses thereof 科吉恩治疗股份有限公司 2025-04-25 — — CN disclosed
CN-119137118-A Antagonists of adenosine receptors 阿道尔克斯治疗有限公司 2024-12-13 — — CN disclosed
CN-118993939-A Tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors 尼坎治疗公司 2024-11-22 — — CN disclosed
CN-118993938-A Tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors 尼坎治疗公司 2024-11-22 — — CN disclosed
CN-118853594-A Chimeric poxvirus compositions and uses thereof 希望之城 2024-10-29 — — CN disclosed
CN-118834840-A Chimeric poxvirus compositions and uses thereof 希望之城 2024-10-25 — — CN disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 — — US disclosed
CN-1457430-A Method and apparatus for in vitro detection and characterization of psychoactive substances using analysis of repetitive electrical activity in neuronal samples MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2003-11-19 — — CN disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 HRH1 2197/4885HTR2A 3941/4885SLC6A4 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.